Concepts (121)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Lymphocyte Subsets | 3 | 2021 | 987 | 0.70 | Why? |
| Granulomatous Disease, Chronic | 2 | 2018 | 60 | 0.35 | Why? |
| Vitamin D | 1 | 2021 | 2904 | 0.30 | Why? |
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 229 | 0.20 | Why? |
| Lopinavir | 4 | 2021 | 4308 | 0.19 | Why? |
| Gout | 1 | 2020 | 85 | 0.19 | Why? |
| Ritonavir | 4 | 2021 | 4212 | 0.19 | Why? |
| Mycobacterium Infections | 1 | 2018 | 72 | 0.18 | Why? |
| Paecilomyces | 1 | 2017 | 9 | 0.18 | Why? |
| Interferon beta-1a | 1 | 2020 | 316 | 0.17 | Why? |
| HIV Protease Inhibitors | 1 | 2020 | 434 | 0.16 | Why? |
| Plasmapheresis | 1 | 2020 | 437 | 0.16 | Why? |
| Mycobacterium bovis | 1 | 2018 | 125 | 0.16 | Why? |
| Thrombotic Microangiopathies | 1 | 2020 | 335 | 0.16 | Why? |
| Severity of Illness Index | 5 | 2021 | 48226 | 0.16 | Why? |
| Aspergillus | 1 | 2018 | 347 | 0.15 | Why? |
| Chemokine CXCL10 | 1 | 2019 | 565 | 0.15 | Why? |
| Pulmonary Alveoli | 1 | 2020 | 867 | 0.15 | Why? |
| Latent Tuberculosis | 1 | 2019 | 324 | 0.14 | Why? |
| Interferon-beta | 1 | 2020 | 979 | 0.14 | Why? |
| Antitubercular Agents | 2 | 2017 | 775 | 0.13 | Why? |
| Tumor Necrosis Factor-alpha | 2 | 2021 | 2483 | 0.13 | Why? |
| Immunoglobulin M | 2 | 2021 | 9091 | 0.13 | Why? |
| Colchicine | 1 | 2020 | 730 | 0.13 | Why? |
| Immunoglobulin G | 3 | 2021 | 21571 | 0.12 | Why? |
| Tuberculosis, Multidrug-Resistant | 1 | 2017 | 433 | 0.12 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.11 | Why? |
| Mycoses | 1 | 2017 | 589 | 0.10 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.10 | Why? |
| Cytokines | 3 | 2021 | 15010 | 0.10 | Why? |
| Pyrazines | 1 | 2021 | 1783 | 0.10 | Why? |
| Dexamethasone | 1 | 2021 | 2055 | 0.10 | Why? |
| Amides | 1 | 2021 | 1864 | 0.10 | Why? |
| Adult | 16 | 2021 | 244371 | 0.10 | Why? |
| Tuberculosis, Pulmonary | 1 | 2019 | 1171 | 0.09 | Why? |
| Aged | 13 | 2021 | 215776 | 0.09 | Why? |
| Immunoglobulins, Intravenous | 1 | 2020 | 2705 | 0.09 | Why? |
| Antiviral Agents | 5 | 2021 | 41703 | 0.09 | Why? |
| Middle Aged | 15 | 2021 | 270681 | 0.09 | Why? |
| Interleukin-6 | 3 | 2021 | 7522 | 0.09 | Why? |
| BCG Vaccine | 1 | 2018 | 1137 | 0.09 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.09 | Why? |
| Coinfection | 2 | 2017 | 6820 | 0.08 | Why? |
| Male | 17 | 2021 | 367725 | 0.08 | Why? |
| Drug Combinations | 3 | 2021 | 3852 | 0.08 | Why? |
| Macrophages | 1 | 2018 | 2784 | 0.08 | Why? |
| Female | 16 | 2021 | 380317 | 0.08 | Why? |
| MicroRNAs | 1 | 2018 | 1787 | 0.07 | Why? |
| Immunologic Factors | 1 | 2020 | 4206 | 0.07 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.07 | Why? |
| Sensitivity and Specificity | 2 | 2021 | 22971 | 0.06 | Why? |
| T-Lymphocytes | 1 | 2020 | 6670 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2021 | 6153 | 0.06 | Why? |
| HIV Infections | 2 | 2017 | 11620 | 0.06 | Why? |
| Humans | 22 | 2021 | 930598 | 0.06 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 13720 | 0.05 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.05 | Why? |
| Biopsy | 2 | 2020 | 2811 | 0.05 | Why? |
| Tetradecanoylphorbol Acetate | 1 | 2018 | 23 | 0.05 | Why? |
| Rhodamines | 1 | 2018 | 19 | 0.05 | Why? |
| Biomarkers | 2 | 2021 | 23361 | 0.05 | Why? |
| DNA, Fungal | 1 | 2018 | 95 | 0.05 | Why? |
| Tuberculin Test | 1 | 2019 | 141 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.05 | Why? |
| Iran | 2 | 2021 | 5467 | 0.04 | Why? |
| Injections, Subcutaneous | 1 | 2020 | 647 | 0.04 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.04 | Why? |
| Respiratory Tract Infections | 1 | 2018 | 6817 | 0.04 | Why? |
| Isoniazid | 1 | 2017 | 105 | 0.04 | Why? |
| T-Lymphocytes, Helper-Inducer | 1 | 2020 | 497 | 0.04 | Why? |
| Drug Therapy, Combination | 2 | 2020 | 7268 | 0.04 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.04 | Why? |
| DNA Mutational Analysis | 1 | 2018 | 581 | 0.04 | Why? |
| Infusions, Intravenous | 1 | 2020 | 1224 | 0.04 | Why? |
| Rifampin | 1 | 2017 | 276 | 0.04 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2017 | 260 | 0.04 | Why? |
| Treatment Failure | 1 | 2021 | 2106 | 0.03 | Why? |
| Cell Survival | 1 | 2020 | 1581 | 0.03 | Why? |
| Lung | 5 | 2020 | 31049 | 0.03 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.03 | Why? |
| Tomography, X-Ray Computed | 4 | 2021 | 25144 | 0.03 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.03 | Why? |
| Administration, Oral | 1 | 2020 | 2340 | 0.03 | Why? |
| Length of Stay | 2 | 2021 | 11042 | 0.03 | Why? |
| Cell Proliferation | 1 | 2020 | 1973 | 0.03 | Why? |
| Reactive Oxygen Species | 1 | 2018 | 1136 | 0.03 | Why? |
| Flow Cytometry | 1 | 2021 | 2393 | 0.03 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.03 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2020 | 4260 | 0.03 | Why? |
| Base Sequence | 1 | 2018 | 3581 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 2309 | 0.02 | Why? |
| Treatment Outcome | 3 | 2020 | 51732 | 0.02 | Why? |
| Pilot Projects | 1 | 2021 | 5182 | 0.02 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2017 | 1115 | 0.02 | Why? |
| Autopsy | 1 | 2020 | 3495 | 0.02 | Why? |
| Mycobacterium tuberculosis | 1 | 2017 | 1164 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2020 | 4758 | 0.02 | Why? |
| Microbial Sensitivity Tests | 1 | 2017 | 2886 | 0.02 | Why? |
| ROC Curve | 1 | 2019 | 6024 | 0.02 | Why? |
| Cells, Cultured | 1 | 2018 | 5835 | 0.02 | Why? |
| Hydroxychloroquine | 2 | 2020 | 12447 | 0.02 | Why? |
| Liver | 1 | 2020 | 4007 | 0.02 | Why? |
| Monocytes | 1 | 2018 | 2978 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 7868 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2019 | 7220 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2021 | 5837 | 0.02 | Why? |
| Neutrophils | 1 | 2018 | 5476 | 0.01 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| Tuberculosis | 1 | 2017 | 2895 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 11367 | 0.01 | Why? |
| Adrenal Cortex Hormones | 1 | 2018 | 6537 | 0.01 | Why? |
| Pandemics | 4 | 2020 | 389249 | 0.01 | Why? |
| Young Adult | 2 | 2020 | 93724 | 0.01 | Why? |
| Retrospective Studies | 2 | 2021 | 105322 | 0.01 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.01 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| Risk Factors | 1 | 2017 | 71621 | 0.01 | Why? |
Marjani's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(121)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(95)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_